

**IMIDAZOLYL DERIVATIVES AS CORTICOTROPIN RELEASING
FACTOR INHIBITORS**

Cross Reference to Related Application

5 This divisional application claims priority from non-provisional
application 10/044,183 filed January 11, 2002, ^{now US Patent 6,888,004,} which claims priority from
provisional application USSN 60/264,570 filed January 26, 2001.

Exam. Amdt
1-8-06

10

Field of the Invention

The present invention relates to antagonists and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor ("CRF receptor") useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache,
15 drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

Background of the Invention

20 It has been shown that the neuropeptide, corticotropin releasing factor ("CRF"), acting through its binding to the CRF-1 receptor, is a primary mediator of stress- and anxiety-related physiological responses in humans and other mammals by stimulating ACTH secretion from the anterior pituitary gland. See A.J. Dunn, et al., Brain Res. Rev., 15: 71-100 (1990). Antagonists of the CRF-1
25 receptor, both peptides (J. Gulyas, et al., Proc. Natl. Acad. Sci. U.S.A., 92: 10575-10579 (1995) and small molecules (J.R. McCarthy, et al., Curr. Pharm. Design, 5: 289-315 (1999), have demonstrated the ability to ameliorate the effects of stressful stimuli in several animal models. In addition, marked elevations of CRF in cerebrospinal fluid have been detected in a large portion of individuals
30 diagnosed with major depression and anxiety disorders, and the levels correlate with severity of the disease. See F. Holsboer, J. Psychiatric Res., 33: 181-214 (1999). Following antidepressant treatment, the increased CRF levels observed

Art Unit: 1624

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

In the specification, page 1, line 7, after the year '2002', insert the phrase -- , now US Patent 6,888,004, --

Please
enter
TNT
1-8-06